Viking Therapeutics, Inc. Operating Leases, Future Minimum Payments, Due in Two Years
Viking Therapeutics, Inc. (VKTX) had Operating Leases, Future Minimum Payments, Due in Two Years of $29.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears · last filed 2021-11-03
- 2021-09-30: Operating Leases, Future Minimum Payments, Due in Two Years $29.00K.
- 2021-06-30: Operating Leases, Future Minimum Payments, Due in Two Years $29.00K.
- 2021-03-31: Operating Leases, Future Minimum Payments, Due in Two Years $29.00K.
- 2020-12-31: Operating Leases, Future Minimum Payments, Due in Two Years $29.00K.
| Period end | Operating Leases, Future Minimum Payments, Due in Two Years |
|---|---|
| 2021-09-30 | $29.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $29.00K 10-Q · filed 2021-07-28 |
| 2021-03-31 | $29.00K 10-Q · filed 2021-04-28 |
| 2020-12-31 | $29.00K 10-K · filed 2021-02-17 |
| 2020-09-30 | $343.00K 10-Q · filed 2020-10-28 |
| 2020-06-30 | $343.00K 10-Q · filed 2020-07-29 |
| 2020-03-31 | $343.00K 10-Q · filed 2020-04-30 |
| 2019-12-31 | $343.00K 10-K · filed 2020-02-26 |
| 2019-09-30 | $333.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $333.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $333.00K 10-Q · filed 2019-05-02 |
| 2018-12-31 | $333.00K 10-K · filed 2019-03-13 |
| 2018-09-30 | $270.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $270.00K 10-Q · filed 2018-08-09 |
| 2017-09-30 | $190.34K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $190.34K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $190.34K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $190.34K 10-K · filed 2017-03-21 |
| 2016-09-30 | $247.61K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $247.61K 10-Q · filed 2016-08-11 |
| 2016-03-31 | $247.61K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $247.61K 10-K · filed 2016-03-08 |
| 2015-09-30 | $199.74K 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |